OTLK
NASDAQOutlook Therapeutics Inc.
Price$0.73-0.04 (-5.10%)
01:30 PM07:45 PM
News · 26 weeks59+64%
2025-12-142026-06-07
Mix3990d
- SEC Filings19(49%)
- Offering7(18%)
- Other6(15%)
- Insider6(15%)
- Analyst1(3%)
Latest news
25 items- INSIDERDirector Haddadin Yezan Munther bought $24,145 worth of shares (29,000 units at $0.83), increasing direct ownership by 78% to 66,167 units (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- INSIDERDirector Sukhtian Ghiath M. bought $5,000,000 worth of shares (8,539,709 units at $0.59) (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- SECSEC Form DEFA14A filed by Outlook Therapeutics Inc.DEFA14A - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECSEC Form DEF 14A filed by Outlook Therapeutics Inc.DEF 14A - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD). As previously announced, Outlook Therapeutics successfully appealed the December 2026 Complete Response Letter (CRL) related to the ONS-5010 Biologics License Application reviewed by the FDA. In their decision,
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECSEC Form 424B5 filed by Outlook Therapeutics Inc.424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesISELIN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8,539,709 shares of its common stock at a purchase price of $0.5855 per share in a registered direct offering priced at-the-market under Nasdaq rules to GMS Ventures and Investments, the Company's largest stockholder. The closing of the offering is expected to occur on or about May 29, 2026, subject to the satisf
- INSIDERDirector Sukhtian Faisal Ghiath bought $50,006 worth of shares (122,174 units at $0.41), increasing direct ownership by 3,593% to 125,574 units (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- INSIDERDirector Haddadin Yezan Munther bought $14,960 worth of shares (34,000 units at $0.44), increasing direct ownership by 1,074% to 37,167 units (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- INSIDERDirector Thurman Randy H bought $2,145 worth of shares (5,000 units at $0.43), increasing direct ownership by 843% to 5,593 units (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- INSIDERDirector Hilzinger Kurt J bought $176,520 worth of shares (400,000 units at $0.44), increasing direct ownership by 1,691% to 423,655 units (SEC Form 4)4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the appeal following completion of the Formal Dispute Resolution (FDR) process with the Office of New Drugs (OND). The FDA concluded that substantial evidence of effectiveness has been established for LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD). As a result, Outlook Therapeutics expects to resubmit the ONS-5010/LYTE
- SECSEC Form PRE 14A filed by Outlook Therapeutics Inc.PRE 14A - Outlook Therapeutics, Inc. (0001649989) (Filer)
- ANALYSTOutlook Therapeutics downgraded by BTIG ResearchBTIG Research downgraded Outlook Therapeutics from Buy to Neutral
- PROutlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdateCompleted Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010; Decision Expected This Month Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe with Commercial Distribution Agreement with Mediconsult AG in SwitzerlandLaunched Real-World Evidence Study in Germany to Further Strengthen the Overall Value Proposition of LYTENAVA™ ISELIN, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for the second quarter of fiscal year 2026 ended March 31, 2026, a
- SECSEC Form 424B5 filed by Outlook Therapeutics Inc.424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECSEC Form D filed by Outlook Therapeutics Inc.D - Outlook Therapeutics, Inc. (0001649989) (Filer)
- SECSEC Form SCHEDULE 13G filed by Outlook Therapeutics Inc.SCHEDULE 13G - Outlook Therapeutics, Inc. (0001649989) (Subject)
- SECOutlook Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
- PROutlook Therapeutics Announces Closing of $5.0 Million Registered Direct OfferingISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics" or the "Company"), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 16,129,033 shares of its common stock at an offering price of $0.31 per share of common stock. Additionally, in a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 16,129,033 shares of common stock at an exercise price
OTLK FAQ
7 questionsWhat does Outlook Therapeutics Inc. do?
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical...Where does OTLK stock trade?
Outlook Therapeutics Inc. (OTLK) is listed on NASDAQ.What sector and industry is OTLK in?
Outlook Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Outlook Therapeutics Inc. go public?
Outlook Therapeutics Inc. (OTLK) completed its IPO in 2016.What are analysts saying about OTLK?
Outlook Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2026-05-18. Recent price targets range from $300.00 to $500.00.What companies are similar to OTLK?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare OTLK side-by-side with any of them on Quantisnow.How can I track OTLK on Quantisnow?
Quantisnow aggregates Outlook Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OTLK to receive live email and push alerts on every new disclosure.